(VRNM, ALGN, GGS) CRWENewswire

Name: (VRNM, ALGN, GGS) CRWENewswire
Uploaded: 2012-01-31
Duration: 1 min 20 s
Description: Verenium Corp - VRNM - reported an agreement with Tate & Lyle for the use of one of its proprietary enzyme products in the development of novel food ingredients. Under the terms of the agreement, Verenium receives $1.5 million in near term milestone payments, revenues from enzyme product sales, and a royalty on Tate & Lyle?s future sales.

karmastock Follow 2

Date: 2012. 01. 31.

Shares: 0 Forwards: 0 Embeds: 1

Category: people & vlogs

Add to list

To Quicklist To Favorites

Embed video

Width

Height

Embed code:

<iframe width="640" height="360" src="//videa.hu/player?v=5iEPWPlaEw02hVSQ" allowfullscreen="allowfullscreen" webkitallowfullscreen="webkitallowfullscreen" mozallowfullscreen="mozallowfullscreen" frameborder="0"></iframe>

Create GIF

Time:

99:99 sec

Resolution:

Crop: Custom 16:9 4:3 Original

Speed (fps): 2 10 20

Create snapshot

New snapshot Download (png) Download (jpg)

Report video

Reason for rejection:

Please provide the following details precisely:

Your full legal name, which typically consists of a surname and a given name, as it appears on a government-issued ID. Videa cannot process the request until it has this information.

The authorized person's email address.

Specify the subject of the grievance and the facts indicating a probable infringement.

I make the following legal declaration:

• I declare that I am acting in good faith, and that the information and statements contained in the notification are accurate and complete.

After verifying the request, Videa will initiate the video removal process.

REPORT

Date: 2012. 01. 31.

Shares: 0

Forwards: 0

Embeds: 1

Tags: algn • ggs • nasdaq:algn • nasdaq:vrnm • nyse:ggs • vrnm

Category: people & vlogs

Verenium Corp - VRNM - reported an agreement with Tate & Lyle for the use of one of its proprietary enzyme products in the development of novel food ingredients. Under the terms of the agreement, Verenium receives $1.5 million in near term milestone payments, revenues from enzyme product sales, and a royalty on Tate & Lyle?s future sales.